ATE526401T1 - Verfahren zur herstellung von proteinen mit freien cysteinresten - Google Patents
Verfahren zur herstellung von proteinen mit freien cysteinrestenInfo
- Publication number
- ATE526401T1 ATE526401T1 AT00902412T AT00902412T ATE526401T1 AT E526401 T1 ATE526401 T1 AT E526401T1 AT 00902412 T AT00902412 T AT 00902412T AT 00902412 T AT00902412 T AT 00902412T AT E526401 T1 ATE526401 T1 AT E526401T1
- Authority
- AT
- Austria
- Prior art keywords
- cysteine residue
- free cysteine
- producing proteins
- proteins
- soluble proteins
- Prior art date
Links
- 235000018102 proteins Nutrition 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 235000018417 cysteine Nutrition 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108091006006 PEGylated Proteins Proteins 0.000 abstract 1
- 239000002981 blocking agent Substances 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11604199P | 1999-01-14 | 1999-01-14 | |
PCT/US2000/000931 WO2000042175A1 (en) | 1999-01-14 | 2000-01-14 | Methods for making proteins containing free cysteine residues |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE526401T1 true ATE526401T1 (de) | 2011-10-15 |
Family
ID=22364893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00902412T ATE526401T1 (de) | 1999-01-14 | 2000-01-14 | Verfahren zur herstellung von proteinen mit freien cysteinresten |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP2305804B1 (pt) |
JP (3) | JP2002534119A (pt) |
KR (1) | KR100731826B1 (pt) |
CN (1) | CN1210400C (pt) |
AT (1) | ATE526401T1 (pt) |
AU (2) | AU775937B2 (pt) |
BR (2) | BR122013003013B8 (pt) |
CA (1) | CA2359345A1 (pt) |
ES (1) | ES2373093T3 (pt) |
IL (3) | IL144259A0 (pt) |
NZ (1) | NZ513077A (pt) |
WO (1) | WO2000042175A1 (pt) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
CA2296770A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
BR122013003013B8 (pt) | 1999-01-14 | 2021-07-06 | Bolder Biotechnology Inc | proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção |
JP4873818B2 (ja) | 2000-05-16 | 2012-02-08 | ボルダー バイオテクノロジー, インコーポレイテッド | 遊離システイン残基を含有するタンパク質をリフォールディングする方法 |
US20040082765A1 (en) | 2000-10-16 | 2004-04-29 | Teruo Nakamura | Peg-modified erythropoietin |
AU3323002A (en) | 2000-12-20 | 2002-07-01 | Hoffmann La Roche | Erythropoietin conjugates |
DE60144439D1 (de) | 2000-12-20 | 2011-05-26 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
JP2004524020A (ja) * | 2001-01-11 | 2004-08-12 | マキシゲン・エイピーエス | 改良された成長ホルモン分子 |
PL362414A1 (en) * | 2001-02-19 | 2004-11-02 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
AU2002356990A1 (en) * | 2001-11-20 | 2003-06-10 | Pharmacia Corporation | Chemically-modified human growth hormone conjugates |
GB2389115B (en) * | 2001-12-14 | 2005-03-16 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone |
BR0308710A (pt) * | 2002-03-26 | 2007-01-09 | Biosynexus Inc | conjugados poliméricos antimicrobianos |
EP1382352A1 (de) * | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein-Konjugate und deren Verwendung |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
TWI281864B (en) * | 2002-11-20 | 2007-06-01 | Pharmacia Corp | N-terminally monopegylated human growth hormone conjugates and process for their preparation |
PL219741B1 (pl) | 2002-12-26 | 2015-07-31 | Mountain View Pharmaceuticals | Sposób zwiększania antyproliferacyjnego potencjału nieglikozylowanego interferonu-beta-1b in vitro, koniugat wytworzony tym sposobem i jego zastosowanie oraz kompozycja farmaceutyczna zawierająca koniugat i jej zastosowanie |
CN1767857A (zh) | 2003-02-26 | 2006-05-03 | 尼克塔治疗亚拉巴马公司 | 聚合物-因子ⅷ部分共轭物 |
SE526214C2 (sv) * | 2003-02-28 | 2005-07-26 | Amersham Biosciences Ab | Ett sätt att generera metallkelaterande affinitetsligander |
DE602004025799D1 (de) | 2003-04-15 | 2010-04-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
CN1826131A (zh) * | 2003-05-30 | 2006-08-30 | 森托科尔公司 | 利用转谷氨酰胺酶形成新的促红细胞生成素缀合物 |
AU2003262552A1 (en) * | 2003-07-29 | 2005-02-25 | Ares Trading S.A. | Use of human growth hormone in multiple system atrophy |
AU2004311796A1 (en) * | 2003-12-31 | 2005-07-21 | Centocor, Inc. | Novel recombinant proteins with N-terminal free thiol |
MXPA06013412A (es) | 2004-05-19 | 2007-01-23 | Maxygen Inc | Polipeptidos de interferon-alfa y conjugados. |
WO2006024953A2 (en) * | 2004-08-31 | 2006-03-09 | Pharmacia & Upjohn Company Llc | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
DK2363414T3 (da) * | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Stedstyret modifikation af FVIII |
EP1848461A2 (en) | 2005-02-16 | 2007-10-31 | Nektar Therapeutics Al, Corporation | Conjugates of an epo moiety and a polymer |
KR20080019619A (ko) | 2005-05-18 | 2008-03-04 | 맥시겐, 인크. | 개량된 인터페론-알파 폴리펩티드 |
KR100694994B1 (ko) | 2005-06-13 | 2007-03-14 | 씨제이 주식회사 | 사람 과립구 콜로니 형성인자 동종체 |
EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
KR100735784B1 (ko) | 2005-07-20 | 2007-07-06 | 재단법인 목암생명공학연구소 | 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물 |
US20090252720A1 (en) * | 2006-05-24 | 2009-10-08 | Novo Nordisk Health Care Ag | Prolonged FIX Analogues and Derivatives |
EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
CN1970572A (zh) | 2006-12-21 | 2007-05-30 | 北京三元基因工程有限公司 | 干扰素α突变体及其聚乙二醇衍生物 |
JP5792951B2 (ja) | 2010-12-16 | 2015-10-14 | キヤノン株式会社 | 振動型アクチュエータの制御装置 |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
EP3808378A1 (en) * | 2011-05-27 | 2021-04-21 | Baxalta GmbH | Therapeutic proteins with increased half-life and methods of preparing same |
EP2793948B1 (en) * | 2011-12-19 | 2022-03-23 | Genzyme Corporation | Thyroid stimulating hormone compositions |
CN103184209B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技(上海)有限公司 | 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用 |
WO2014039010A1 (en) * | 2012-09-04 | 2014-03-13 | Republic Polytechnic | Isolated oligonucleotides, methods and kits for detection, identification and/or quantitation of chikungunya and dengue viruses |
WO2015086853A1 (en) * | 2013-12-13 | 2015-06-18 | Novo Nordisk Health Care Ag | Method for thioether conjugation of proteins |
CN107106656A (zh) * | 2014-10-29 | 2017-08-29 | 梯瓦制药澳大利亚股份有限公司 | 干扰素α2b变体 |
CN107614007B (zh) * | 2015-05-15 | 2022-03-25 | 免疫医疗有限责任公司 | 改进的尿酸酶序列和治疗方法 |
CA2938333A1 (en) * | 2015-08-12 | 2017-02-12 | Pfizer Inc. | Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation |
CN106924753B (zh) * | 2015-12-30 | 2021-11-09 | 北京大学 | 制备蛋白质-聚氨基酸环状偶联物的方法 |
US20190381182A1 (en) * | 2017-02-08 | 2019-12-19 | Pfizer Inc. | Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation |
CN111172184A (zh) * | 2020-03-10 | 2020-05-19 | 大连理工大学 | 一种基于基因修饰得到人重组干扰素的融合基因、融合蛋白及其制备方法 |
CN112812963A (zh) * | 2021-01-28 | 2021-05-18 | 美康生物科技股份有限公司 | 一种总同型半胱氨酸测试卡 |
CN115417917A (zh) * | 2021-05-30 | 2022-12-02 | 中国科学院上海药物研究所 | 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5016321B1 (pt) * | 1969-05-10 | 1975-06-12 | ||
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
DE3540076A1 (de) * | 1985-11-12 | 1987-05-14 | Boehringer Mannheim Gmbh | Verfahren zur stabilisierung von creatinkinase |
JPH01132598A (ja) * | 1987-10-14 | 1989-05-25 | Pitman Moore Inc | 変性剤溶液中に含まれる組換え蛋白質における分子内ジスルフィド結合の生成を促進する方法 |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US5130418A (en) * | 1989-05-02 | 1992-07-14 | California Biotechnology Inc. | Method to stabilize basic fibroblast growth factor |
US5235043A (en) * | 1990-04-06 | 1993-08-10 | Synergen, Inc. | Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5837539A (en) † | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
DE4113750A1 (de) * | 1991-04-26 | 1992-10-29 | Boehringer Mannheim Gmbh | Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen |
US7018809B1 (en) * | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
WO1993020200A1 (en) † | 1992-04-02 | 1993-10-14 | Imperial Cancer Research Technology Limited | Modified cells and method of treatment |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
KR950703999A (ko) * | 1992-11-25 | 1995-11-17 | 토마스 이. 워크맨 주니어 | 변성된 인슐린-유사 성장인자(modified insulin-like growth factors) |
AU6626794A (en) | 1993-04-07 | 1994-10-24 | Amgen Boulder Inc. | Methods of using insulin-like growth factor binding proteins |
AU685187B2 (en) * | 1993-10-29 | 1998-01-15 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
US6207640B1 (en) * | 1994-04-07 | 2001-03-27 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
CA2190752A1 (en) * | 1994-05-24 | 1995-11-30 | George N. Cox | Modified insulin-like growth factors |
EP1845108A3 (en) * | 1994-07-29 | 2007-10-24 | Innogenetics N.V. | Monoclonal antibodies to purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
ES2273338T3 (es) * | 1994-10-13 | 2007-05-01 | Amgen Inc. | Metodo para el tratamiento de la diabetes mellitus usando kfg. |
JPH11505805A (ja) * | 1995-05-16 | 1999-05-25 | プリズム ファーマシューティカルズ,インコーポレイテッド | 治療的処置のための核酸およびリガンドを含有する組成物 |
JPH11514223A (ja) * | 1995-09-22 | 1999-12-07 | イムノメディクス,インコーポレイテッド | 複数のジスルフィド結合を有する組換えタンパク質およびそのチオール置換複合体 |
GB9625640D0 (en) * | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
AU746819B2 (en) * | 1997-02-21 | 2002-05-02 | Genentech Inc. | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
CA2296770A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
BR122013003013B8 (pt) | 1999-01-14 | 2021-07-06 | Bolder Biotechnology Inc | proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção |
WO2006024953A2 (en) | 2004-08-31 | 2006-03-09 | Pharmacia & Upjohn Company Llc | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
EP2040757A2 (en) | 2006-07-07 | 2009-04-01 | Novo Nordisk Health Care AG | New protein conjugates and methods for their preparation |
CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
EP3019533B1 (en) | 2013-07-11 | 2020-01-08 | The Scripps Research Institute | Coiled coil immunoglobulin fusion proteins and compositions thereof |
-
2000
- 2000-01-14 BR BR122013003013A patent/BR122013003013B8/pt not_active IP Right Cessation
- 2000-01-14 AU AU24133/00A patent/AU775937B2/en not_active Ceased
- 2000-01-14 WO PCT/US2000/000931 patent/WO2000042175A1/en active Application Filing
- 2000-01-14 ES ES00902412T patent/ES2373093T3/es not_active Expired - Lifetime
- 2000-01-14 NZ NZ513077A patent/NZ513077A/xx not_active IP Right Cessation
- 2000-01-14 EP EP20100012486 patent/EP2305804B1/en not_active Revoked
- 2000-01-14 JP JP2000593732A patent/JP2002534119A/ja active Pending
- 2000-01-14 EP EP00902412.6A patent/EP1144613B2/en not_active Expired - Lifetime
- 2000-01-14 IL IL14425900A patent/IL144259A0/xx unknown
- 2000-01-14 KR KR1020017008951A patent/KR100731826B1/ko active IP Right Grant
- 2000-01-14 CA CA002359345A patent/CA2359345A1/en not_active Abandoned
- 2000-01-14 BR BRPI0008759-9A patent/BR0008759B1/pt not_active IP Right Cessation
- 2000-01-14 CN CNB008088411A patent/CN1210400C/zh not_active Expired - Fee Related
- 2000-01-14 AT AT00902412T patent/ATE526401T1/de not_active IP Right Cessation
-
2001
- 2001-07-11 IL IL144259A patent/IL144259A/en not_active IP Right Cessation
-
2004
- 2004-11-19 AU AU2004231217A patent/AU2004231217B2/en not_active Ceased
-
2008
- 2008-10-02 IL IL194483A patent/IL194483A0/en unknown
-
2010
- 2010-09-02 JP JP2010196790A patent/JP5517844B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-20 JP JP2014007656A patent/JP2014064594A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2373093T3 (es) | 2012-01-31 |
EP2305804A1 (en) | 2011-04-06 |
JP2010280714A (ja) | 2010-12-16 |
KR100731826B1 (ko) | 2007-06-22 |
EP1144613B1 (en) | 2011-09-28 |
IL144259A (en) | 2009-06-15 |
EP1144613A4 (en) | 2002-10-29 |
JP2014064594A (ja) | 2014-04-17 |
CN1210400C (zh) | 2005-07-13 |
AU2004231217A1 (en) | 2004-12-23 |
JP5517844B2 (ja) | 2014-06-11 |
JP2002534119A (ja) | 2002-10-15 |
CA2359345A1 (en) | 2000-07-20 |
WO2000042175A1 (en) | 2000-07-20 |
EP2305804B1 (en) | 2015-05-06 |
KR20020011364A (ko) | 2002-02-08 |
EP1144613A1 (en) | 2001-10-17 |
EP1144613B2 (en) | 2020-05-06 |
BR122013003013B8 (pt) | 2021-07-06 |
BR122013003013B1 (pt) | 2015-06-30 |
AU775937B2 (en) | 2004-08-19 |
IL144259A0 (en) | 2002-05-23 |
BR0008759A (pt) | 2002-08-06 |
CN1355842A (zh) | 2002-06-26 |
NZ513077A (en) | 2004-03-26 |
AU2413300A (en) | 2000-08-01 |
AU2004231217B2 (en) | 2008-02-28 |
IL194483A0 (en) | 2011-08-01 |
BR0008759B1 (pt) | 2014-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE526401T1 (de) | Verfahren zur herstellung von proteinen mit freien cysteinresten | |
ATE367398T1 (de) | Verfahren zur rückfaltung von proteinen mit freien cysteinresten | |
DE69016590T2 (de) | Verfahren zur Herstellung von Acrylsäure. | |
DE50005699D1 (de) | Verfahren zur herstellung von thiazolidin | |
DE3854004D1 (de) | Verfahren zur Herstellung von N-substituiertem Amin. | |
DE69115862T2 (de) | Verfahren zur Herstellung von Methacrylsäure | |
DE69004582D1 (de) | Verfahren zur Herstellung von alpha-Hydroxycarbonsäure-Amid. | |
DE69120660T2 (de) | Verfahren zur herstellung von aminosäure-salzen | |
DE69131376D1 (de) | Verfahren zur Herstellung von doppelt-diffundierten integrierten MOSFET-Zellen | |
DE69001623T2 (de) | Verfahren zur Herstellung von Fluor-oxy-fluorsulfonylverbindungen durch direkte Fluorierung von Fluor-beta-sultonen. | |
DE50105185D1 (de) | Verfahren zur Herstellung von Dithiazolyldisulfiden | |
DE59001820D1 (de) | Verfahren zur herstellung von indolcarbonsaeurederivaten. | |
FI895921A0 (fi) | Enzymhaemmande aminosyraderivat, foerfarande foer deras framstaellning, dessa innehaollande aemnen och deras anvaendning. | |
DE69021239T2 (de) | Verfahren zur Herstellung von ellagischer Säure. | |
DE68914236D1 (de) | Verfahren zur Herstellung von Natriumhyaluronat durch Gärung. | |
DE59004490D1 (de) | Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten. | |
DE69121028T2 (de) | Verfahren zur herstellung von methacrylsäure | |
DE60133395D1 (de) | Verfahren zur herstellung von alpha'-chlorketonen | |
DE3767764D1 (de) | Verfahren zur herstellung von n-acryloyl-alpha-aminosaeuren. | |
DE69002772D1 (de) | Verfahren zur herstellung von zinkoxid-whiskern. | |
DE59803194D1 (de) | Verfahren zur herstellung von 1,3-disubstituierten 2-nitroguanidinen | |
DE59000635D1 (de) | Verfahren zur herstellung von natriummonosulfid. | |
DE59001152D1 (de) | Verfahren zur herstellung von nitro-benzoesaeure-alkylestern. | |
DE69019325D1 (de) | Verfahren zur Herstellung von Alkohol oder Amin. | |
DD136498A1 (de) | Verfahren zur herstellung von hochgereinigtem fluorescein fuer injektionszwecke |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |